Bioventus Inc. (BVS)
After hours:
| Previous close | 5.12 |
| Open | 5.40 |
| Bid | 5.01 x 200 |
| Ask | 5.07 x 100 |
| Day's range | 4.91 - 5.49 |
| 52-week range | 1.01 - 6.08 |
| Volume | |
| Avg. volume | 203,450 |
| Market cap | 321.691M |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Bioventus Reports First Quarter Financial Results
Raises Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic PrioritiesAccelerated First Quarter Revenue Growth by 8.7%, Organic Growth* by 15.3%Gross Margin Expanded 620 bps and Adjusted Gross Margin* 190 bps DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024. “We ar
- GlobeNewswire
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-8
- GlobeNewswire
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
Accelerated fourth quarter sales growth to 7.6%, organic growth* of 14.3%Appointed Rob Claypoole as President and Chief Executive Officer, bringing more than 20 years of leadership experience in the global medical device industryProvides full-year 2024 financial guidance reflecting enhanced revenue growth and improved execution DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today ann
